These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1139 related articles for article (PubMed ID: 28391418)

  • 1. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
    Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin.
    Song Z; Fu W; Zhou L
    BMC Gastroenterol; 2019 Jul; 19(1):132. PubMed ID: 31345165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
    Gisbert JP; Romano M; Gravina AG; Solís-Muñoz P; Bermejo F; Molina-Infante J; Castro-Fernández M; Ortuño J; Lucendo AJ; Herranz M; Modolell I; Del Castillo F; Gómez J; Barrio J; Velayos B; Gómez B; Domínguez JL; Miranda A; Martorano M; Algaba A; Pabón M; Angueira T; Fernández-Salazar L; Federico A; Marín AC; McNicholl AG
    Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori.
    Wu TS; Hsu PI; Kuo CH; Hu HM; Wu IC; Wang SSW; Chen YH; Wu DC; Su WW; Kuo FC
    J Dig Dis; 2017 Sep; 18(9):537-542. PubMed ID: 28644575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
    BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
    Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial.
    Su J; Zhou X; Chen H; Hao B; Zhang W; Zhang G
    Medicine (Baltimore); 2017 Feb; 96(7):e5859. PubMed ID: 28207505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New regimens as first-line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trial.
    Zhang Y; Suo B; Tian X; Zhang H; Lu H; Yao X; Li C; Ren X; Zhou L; Song Z
    Helicobacter; 2023 Apr; 28(2):e12956. PubMed ID: 36752304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: A Prospective, Single-Center, randomized clinical trial.
    Gan HY; Peng TL; Huang YM; Su KH; Zhao LL; Yao LY; Yang RJ
    Sci Rep; 2018 Jun; 8(1):9045. PubMed ID: 29899426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
    Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
    Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
    Zhang D; Ke L; Ni Z; Chen Y; Zhang LH; Zhu SH; Li CJ; Shang L; Liang J; Shi YQ
    Medicine (Baltimore); 2017 Aug; 96(32):e7697. PubMed ID: 28796053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
    Chuah SK; Tai WC; Hsu PI; Wu DC; Wu KL; Kuo CM; Chiu YC; Hu ML; Chou YP; Kuo YH; Liang CM; Chiu KW; Hu TH
    Helicobacter; 2012 Oct; 17(5):374-81. PubMed ID: 22967121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication.
    Song Z; Suo B; Zhang L; Zhou L
    Helicobacter; 2016 Dec; 21(6):462-470. PubMed ID: 27060292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study.
    De Francesco V; Pontone S; Bellesia A; Serviddio G; Panetta C; Palma R; Zullo A
    Dig Liver Dis; 2018 Feb; 50(2):139-141. PubMed ID: 29089267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial.
    Yu L; Luo L; Long X; Liang X; Ji Y; Graham DY; Lu H
    Helicobacter; 2019 Aug; 24(4):e12596. PubMed ID: 31111580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetracycline Three Times Daily Versus Four Times Daily in Bismuth-Containing Quadruple Therapy as the First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial.
    Ding YM; Zhang QM; Li RL; Han ZX; Zhao Q; Xu LD; Wang KY; Nan XP; Duan M; Zeng SY; Kong QZ; Wang H; Wu XQ; Zhang N; Li YQ; Zuo XL; Li YY
    Helicobacter; 2024; 29(4):e13121. PubMed ID: 39097924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments.
    Gisbert JP; Romano M; Molina-Infante J; Lucendo AJ; Medina E; Modolell I; Rodríguez-Tellez M; Gomez B; Barrio J; Perona M; Ortuño J; Ariño I; Domínguez-Muñoz JE; Perez-Aisa Á; Bermejo F; Domínguez JL; Almela P; Gomez-Camarero J; Millastre J; Martin-Noguerol E; Gravina AG; Martorano M; Miranda A; Federico A; Fernandez-Bermejo M; Angueira T; Ferrer-Barcelo L; Fernández N; Marín AC; McNicholl AG
    Dig Liver Dis; 2015 Feb; 47(2):108-13. PubMed ID: 25454706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
    Song Z; Zhou L; Xue Y; Suo B; Tian X; Niu Z
    Helicobacter; 2020 Dec; 25(6):e12762. PubMed ID: 33040439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.
    Chen Q; Zhang W; Fu Q; Liang X; Liu W; Xiao S; Lu H
    Am J Gastroenterol; 2016 Dec; 111(12):1736-1742. PubMed ID: 27670603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.